What caused the pre-market spike in TMD.TO stock?

The spike to C$1.125 in pre-market trading came from heavy volume (117,220.00 shares) and renewed interest in Titan Medical’s Enos program; no single confirmed press release was filed at the time of the move.

What is the Meyka AI price forecast for TMD.TO stock?

Meyka AI's forecast model projects C$1.85 for TMD.TO stock in the short term, implying an upside of 64.44% from C$1.125. Forecasts are model-based projections and not guarantees.

Is TMD.TO stock fundamentally strong?

Titan Medical shows a current ratio of 2.78 and low debt to equity (0.28), but negative EPS (-1.73) and high P/B (19.42) reflect limited revenue and elevated valuation risk for TMD.TO stock.

How should traders manage risk in TMD.TO stock?

Use position sizing, tight stop-losses, and watch volume confirmation; high intraday swings and potential dilution make TMD.TO stock a high-risk tradable, not a buy-and-hold for most investors.

CA Stocks

Pre-market 06 Feb 2026 TSX: Titan Medical Inc. (TMD.TO) C$1.125 volume spike: watch liquidity

ByHuzaifa Zahoor February 6, 2026February 6, 2026

TMD.TO stock opened the TSX pre-market at C$0.05 and jumped to C$1.125 on 06 Feb 2026, driven by a sharp intraday volume surge of 117,220.00 shares versus an average of 45,936.00. That spike lifted market cap to roughly C$128,295,000.00 and pushed the share price well above its 50-day average of C$0.07. For traders watching high-volume movers, the combination of low float, news sensitivity around Titan Medical Inc.’s Enos robotic program, and a big relative volume of 2.55x creates a fast-moving short-term trade environment. We outline the catalysts, fundamentals, risks and a model forecast below.